153 related articles for article (PubMed ID: 37875322)
1. Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework.
Bruno V; Betti M; D'Ambrosio L; Massacci A; Chiofalo B; Pietropolli A; Piaggio G; Ciliberto G; Nisticò P; Pallocca M; Buda A; Vizza E
Int J Gynecol Cancer; 2023 Nov; 33(11):1708-1714. PubMed ID: 37875322
[TBL] [Abstract][Full Text] [Related]
2. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
3. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
4. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
5. Preoperative MR imaging for ESMO-ESGO-ESTRO classification of endometrial cancer.
Lavaud P; Fedida B; Canlorbe G; Bendifallah S; Darai E; Thomassin-Naggara I
Diagn Interv Imaging; 2018 Jun; 99(6):387-396. PubMed ID: 29472031
[TBL] [Abstract][Full Text] [Related]
6. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
[TBL] [Abstract][Full Text] [Related]
7. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
[TBL] [Abstract][Full Text] [Related]
9. Developing and validating ultrasound-based radiomics models for predicting high-risk endometrial cancer.
Moro F; Albanese M; Boldrini L; Chiappa V; Lenkowicz J; Bertolina F; Mascilini F; Moroni R; Gambacorta MA; Raspagliesi F; Scambia G; Testa AC; Fanfani F
Ultrasound Obstet Gynecol; 2022 Aug; 60(2):256-268. PubMed ID: 34714568
[TBL] [Abstract][Full Text] [Related]
10. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Concin N; Creutzberg CL; Vergote I; Cibula D; Mirza MR; Marnitz S; Ledermann JA; Bosse T; Chargari C; Fagotti A; Fotopoulou C; González-Martín A; Lax SF; Lorusso D; Marth C; Morice P; Nout RA; O'Donnell DE; Querleu D; Raspollini MR; Sehouli J; Sturdza AE; Taylor A; Westermann AM; Wimberger P; Colombo N; Planchamp F; Matias-Guiu X
Virchows Arch; 2021 Feb; 478(2):153-190. PubMed ID: 33604759
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
12. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion.
Bendifallah S; Canlorbe G; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Huguet F; Cortez A; Daraï E; Ballester M
Br J Cancer; 2014 May; 110(11):2640-6. PubMed ID: 24809776
[TBL] [Abstract][Full Text] [Related]
13. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence.
Ouh YT; Oh Y; Joo J; Woo JH; Han HJ; Cho HW; Lee JK; Chun Y; Lim MN; Hong JH
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473326
[TBL] [Abstract][Full Text] [Related]
14. Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology in early-stage endometrial cancer.
Daix M; Angeles MA; Migliorelli F; Kakkos A; Martinez Gomez C; Delbecque K; Mery E; Tock S; Gabiache E; Decuypere M; Goffin F; Martinez A; Ferron G; Kridelka F
J Gynecol Oncol; 2021 Jul; 32(4):e48. PubMed ID: 33908709
[TBL] [Abstract][Full Text] [Related]
15. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.
Colombo N; Creutzberg C; Amant F; Bosse T; González-Martín A; Ledermann J; Marth C; Nout R; Querleu D; Mirza MR; Sessa C;
Radiother Oncol; 2015 Dec; 117(3):559-81. PubMed ID: 26683800
[TBL] [Abstract][Full Text] [Related]
16. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.
Colombo N; Creutzberg C; Amant F; Bosse T; González-Martín A; Ledermann J; Marth C; Nout R; Querleu D; Mirza MR; Sessa C;
Int J Gynecol Cancer; 2016 Jan; 26(1):2-30. PubMed ID: 26645990
[TBL] [Abstract][Full Text] [Related]
17. Vaginal brachytherapy management of stage I and II endometrial cancer.
van den Heerik ASVM; Horeweg N; Creutzberg CL; Nout RA
Int J Gynecol Cancer; 2022 Mar; 32(3):304-310. PubMed ID: 35256416
[TBL] [Abstract][Full Text] [Related]
18. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
19. It is time to implement molecular classification in endometrial cancer.
Bruno V; Logoteta A; Chiofalo B; Mancini E; Betti M; Fabrizi L; Piccione E; Vizza E
Arch Gynecol Obstet; 2024 Mar; 309(3):745-753. PubMed ID: 37410149
[TBL] [Abstract][Full Text] [Related]
20. The Significance of International Federation of Gynecology and Obstetrics Grading in Microsatellite Instability-High and POLE-Mutant Endometrioid Endometrial Carcinoma.
Kertowidjojo E; Momeni-Boroujeni A; Rios-Doria E; Abu-Rustum N; Soslow RA
Mod Pathol; 2023 Sep; 36(9):100234. PubMed ID: 37268062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
